For the 2020 reporting year, the following ASCO-developed measures are available in the MIPS reporting program. The CMS QPP website lists the complete MIPS Oncology Measures Set.

MIPS Clinical Quality Measures (CQMs)

These measures are available for reporting to CMS using the QOPI Reporting Registry, EHR, and other registries

Quality ID

Measure

144

(NQF 0383)

Oncology: Medical and Radiation - Plan of Care for Moderate to Severe Pain

450

(NQF 1858)

Trastuzumab Received By Patients With AJCC Stage I (T1c) - III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy

451

(NQF 1859)

RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy

452

(NQF 1860)

Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies

453

(NQF 0210)

Percentage of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score - better)

455

(NQF 0213)

Percentage of Patients Who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life (lower score - better)

457

(NQF 0216)

Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score - better)

 

QOPI Reporting Registry QCDR Measures

These measures can be reported to CMS only using the QOPI Reporting Registry. Find out more about the QOPI Reporting Registry and the additional measures available.